Skip to main content
Clinical Trials/NCT05615610
NCT05615610
Recruiting
Not Applicable

A Randomized Controlled Clinical Trial of Transcutaneous Electrical Nerve Stimulation on Cognitive Function and Upper Limb Motor Function in People With Chronic Stroke

The Hong Kong Polytechnic University1 site in 1 country90 target enrollmentNovember 1, 2023
ConditionsChronic Stroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Stroke
Sponsor
The Hong Kong Polytechnic University
Enrollment
90
Locations
1
Primary Endpoint
Fugl-Meyer Assessment of the Upper Extremity
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

Upper limb impairment is present in more than 85% of people with stroke, which greatly affect the quality of life, social participation, and performance of daily activities of people with stroke. Previous study also revealed that 53.4% of people after stroke experienced cognitive impairment. Different cognitive domains might be affected following stroke, such as attention, memory, language, and orientation, and the problems with memory are often prominent. Yet, there is no effective treatment for the post-stroke cognitive impairment.

Transcutaneous spinal cord stimulation (tSCS) and transcutaneous vagus nerve stimulation (tVNS) are simple and non-invasive treatment to improve upper limb motor function and cognitive function. However, no existing studies have explored on the effects of tSCS and tVNS on cognitive function in people with stroke. Therefore, the purpose of this study is to evaluate the effectiveness of transcutaneous electrical nerve stimulation (TENS) on improving upper limb function and cognitive function in people with chronic stroke.

Detailed Description

This study aims to investigate the effects of three intervention protocols in people with stroke. The participants in Group A will receive tSCS on C6 and T5 level of the spine with upper limb exercises. The participants in Group B will receive tVNS on the cymba conchae of left outer ear with upper limb exercises. The participants in Group C will receive placebo stimulation with upper limb exercises.

Registry
clinicaltrials.gov
Start Date
November 1, 2023
End Date
December 15, 2025
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • aged between 50 and 80;
  • have suffered from a single stroke at least 6 months;
  • had volitional control of the non-paretic arm and at least minimal antigravity movement in the paretic shoulder;

Exclusion Criteria

  • have cardiac pacemaker or cochlear implant;
  • have other neurological diseases;
  • are taking medication that may affect measured outcomes;
  • have skin lesions, infection, or inflammation near selected position;
  • are participating in other drug/treatment programs.

Outcomes

Primary Outcomes

Fugl-Meyer Assessment of the Upper Extremity

Time Frame: 1-month follow-up (10 week)

The Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) assesses the motor control, which included the reflex, synergistic and isolated movements and coordination of the upper extremity. It is a 3-point ordinal scale with 33 items and the total score ranges from 0 to 66. In this scale, "0" represents "cannot perform", "1" represents "performs partially" and "2" represents "performs fully". The higher score indicates better motor control of the upper extremity. The FMA-UE has an excellent inter-rater reliability (ICC = 0.98) in people with stroke.

Montreal Cognitive Assessment

Time Frame: 1-month follow-up (10 week)

The Montreal Cognitive Assessment (MoCA) is a screening tool to detect cognitive impairment of an individual with a total score of 30. The MoCA assesses different cognitive domains, including executive functioning, immediate and delayed memory, visuospatial abilities, attention, working memory, language, and orientation to time and place. It can identify dementia from controls with a sensitivity of 92.3% and specificity of 91.8% with a cut-off score of 22.

Secondary Outcomes

  • Wolf Motor Function Test(1-month follow-up (10 week))
  • Muscle strength(Mid-intervention (3 week))
  • Digit Span Test(Baseline (0 week))
  • Arm Activity Measure(Baseline (0 week))
  • 12-item Short-Form Survey (second version)(Baseline (0 week))
  • Rivermead Behavioural Memory Test - Third edition(1-month follow-up (10 week))
  • Oxford Participation and Activities Questionnaire(Baseline (0 week))
  • Trail Making Test(Baseline (0 week))
  • Muscle stiffness(Baseline (0 week))

Study Sites (1)

Loading locations...

Similar Trials